These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33407304)

  • 1. Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report.
    Harada M; Naoi H; Yasuda K; Ito Y; Kagoo N; Kubota T; Ichijo K; Mochizuki E; Uehara M; Matsuura S; Tsukui M; Koshimizu N
    BMC Pulm Med; 2021 Jan; 21(1):6. PubMed ID: 33407304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.
    Jodai T; Yoshida C; Sato R; Kakiuchi Y; Sato N; Iyama S; Kimura T; Saruwatari K; Saeki S; Ichiyasu H; Fujii K; Tomita Y
    Immun Inflamm Dis; 2019 Mar; 7(1):3-6. PubMed ID: 30461210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
    J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M
    J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report.
    Yasuoka S; Hamasaki T; Kuribayashi E; Nagasawa M; Kawaguchi T; Nagashima Y; Kondo Y
    Medicine (Baltimore); 2018 Nov; 97(45):e13173. PubMed ID: 30407350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma.
    Irifuku T; Satoh A; Tani H; Mandai K; Masaki T
    CEN Case Rep; 2020 Feb; 9(1):48-54. PubMed ID: 31605271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report.
    Abe K; Ishikawa Y; Fujiwara M; Yukawa H; Yanagihara T; Takei S; Arioka H; Kita Y
    Medicine (Baltimore); 2022 Jan; 101(2):e28428. PubMed ID: 35029182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment-related Skin Toxicity Caused by Programmed Death-1 Inhibitor Nivolumab: 
A Case Report].
    Gao L; Yu Y; Lu S
    Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):250-254. PubMed ID: 31014445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.
    Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M
    Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
    Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
    [No Abstract]   [Full Text] [Related]  

  • 11. Case 286: Sarcoidlike Granulomatosis and Lymphadenopathy-Thoracic Manifestations of Nivolumab Drug Toxicity.
    Chiang J; Hebroni F; Bedayat A; Pourzand L
    Radiology; 2021 Feb; 298(2):471-475. PubMed ID: 33493088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
    Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
    World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An uncommon presentation of eosinophilic granulomatosis with polyangiitis: a case report.
    Taormina G; Andolina G; Banco MA; Costanza-Gaglio EJ; Bonura A; Buscemi S
    J Med Case Rep; 2014 Jun; 8():190. PubMed ID: 24928069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study.
    Gane E; Verdon DJ; Brooks AE; Gaggar A; Nguyen AH; Subramanian GM; Schwabe C; Dunbar PR
    J Hepatol; 2019 Nov; 71(5):900-907. PubMed ID: 31306680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy.
    Domblides C; Gross-Goupil M; Ravaud A; Poullenot F; Daste A
    Immunotherapy; 2021 Jun; 13(9):741-744. PubMed ID: 33906378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. So slow, so fast, a case of nivolumab-induced hypothyroidism with subsequent rhabdomyolysis.
    Abushalha K; Abulaimoun S; Silberstein PT
    Immunotherapy; 2020 Jun; 12(9):625-628. PubMed ID: 32418490
    [No Abstract]   [Full Text] [Related]  

  • 17. Pulmonary sarcoid-like granulomatosis induced by nivolumab.
    Montaudié H; Pradelli J; Passeron T; Lacour JP; Leroy S
    Br J Dermatol; 2017 Apr; 176(4):1060-1063. PubMed ID: 27291635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
    Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
    J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapsing polychondritis after treatment with PD-1 blockade.
    Ogimoto T; Yoshida H; Mizuta M; Hirai T
    Invest New Drugs; 2022 Apr; 40(2):389-391. PubMed ID: 34562229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.